WuXi Biologics successfully held the "Continuous Innovation - Empowering R&D" Summit Forum

-- From target to PCC, how can it be good and fast?

SHANGHAI, Nov.
22, 2022 /PRNewswire/ -- WuXi Biologics recently held the R-Day "Continuous Innovation and Empowering R&D" Summit as one of the sub-forums of the Zhangjiang Life Science International Innovation Summit of Shanghai International Biomedical Industry Week
.
The forum focused on topics such as "How to Continue New Drug Innovation and Empower Early Molecular Discovery in the Current Challenging Environment" and "The Outlook of Primary and Secondary Investment in the Pharmaceutical Industry in the New Era", and invited relevant experts and scholars in the industry to conduct in-depth discussions
.

As one of the important sub-forums of the shared and open section of the "Zhangjiang Life Science International Innovation Summit", this forum attracted more than 100 professionals to share and discuss cutting-edge technologies and insights in the field of biomedicine from different perspectives, and jointly explore how to use appropriate business models to solve R&D challenges and accelerate drug innovation
.

Dr.
Jijie Gu, Executive Vice President and Chief Scientific Officer of WuXi Biologics, delivered a welcome speech and delivered a keynote speech
entitled "Creating a New Era of CRDMO".
Dr.
Gu Jijie said that the biomedical industry is one of the emerging industries in China and one of
the industries with the most growth potential.
At present, affected by the global epidemic, capital winter and other factors, the biomedical industry is facing multiple challenges
.
Despite this, biotechnology continues to make breakthroughs, and the development of technology platforms and new therapies such as ADCs, bispecific antibodies, and mRNA is still in full swing
.
WuXi Biologics continues to accelerate the development and manufacturing
of biologics worldwide through technological innovation.
To better serve the needs of pharmaceutical companies at different stages, WuXi Biologics has built the world's leading CRDMO technology platform to provide global partners with one-stop service
from concept to commercial production.
Supported by this unique model, the company's commercial manufacturing projects have exploded, with a significant increase
in early and late stage clinical programs.

In today's fast-changing pharmaceutical industry, drug discovery requires a higher level of expertise from life science service providers
.
Dr.
Zhuozhi Wang, Vice President of WuXi Biologics' New Drug R&D Services Group, shared his insights
on "Multi-antibody Discovery and Optimization Platform for Biopharmaceutical Innovation".
WuXi Biologics Discovery Services provides industry-leading biologics development services with a dedicated team of more than 400 scientists with extensive industry experience and state-of-the-art equipment
.
The company provides customers with high-quality services through advanced technology platforms, including monoclonal fully human antibody discovery, humanization of murine antibodies, druggability analysis and modification, production of various antibody-derived biological drugs, in vitro biological testing, and the use of various animal models to detect efficacy and pharmacokinetics
.

Dr.
Jiawei Lu, Director of WuXi Biologics R&D Services, Dr.
Yongsheng Xiao, Senior Director of WuXi Biologics' Protein Science Division, and Dr.
Tao Li, Senior Director of WuXi Biologics' mRNA Technology Platform, further introduced "Enabling Innovation and Accelerating R&D - WuXi Synthesis Conjugate Drug Integrated R&D Service Platform", "Challenges and Strategies for Early R&D of Recombinant Protein and Antibody Manufacturing" and "Establishing a Microbial and mRNA Technology Platform to Support the R&D and Production of New Biologics"
, respectively.

In the past year, the pharmaceutical investment market has been calm on the surface, but in fact there has been an undercurrent
.
In the future, will pharmaceutical investment continue to blow out, or will it gradually return to calm and cautious? Where will the next pharmaceutical investment outlet? Dr.
Xu Jiaxi, Managing Director of Industrial Securities, shared the outlook
of primary and secondary investment in the pharmaceutical industry in the new era.
From the perspective of capital market, Dr.
Xu Jiaxi explained the current market and industry environment and future trends
in detail, focusing on the long-cycle and short-cycle driving factors of the pharmaceutical industry, grasping the innovation dividend and engineer dividend under supply upgrading.

At the end of the event, under the chairmanship of Dr.
Gu Jijie, Dr.
Zhongyuan Zhu, founder and CEO of Yingen Biotechnology, Dr.
Yongxin Zhao, President of Hangzhou Duoxi Biologics, Mr.
Zhao Min, Vice President of CMC of Innolake Pharmaceutical, Dr.
Wang Zhuozhi and Dr.
Xu Jiaxi jointly conducted a wonderful roundtable discussion
entitled "How to Continue New Drug Innovation and Empower Early Molecular Discovery in the Current Challenging Environment" 。 Experts shared wonderful views and exchanged views with on-site participants on topics such as the severe challenges facing new drug R&D, how to improve the efficiency and production of new drug R&D
, how China's pharmaceutical industry has changed from a pharmaceutical country to a pharmaceutical power, and how to stand out from the competition through resource integration in the period of industry transformation.

The highlights of this conference will also be broadcast in the form of a recorded broadcast on WuXi Biologics' WeChat public account (WuXiBio_Marketing) "WuXi Biologics Vision" and float biologics language columns, welcome to follow WuXi Biologics' latest push
from Marketing Department.

About WuXi Biologics

WuXi Biologics (stock code: 2269.
HK) is a leading global contract research, development and manufacturing (CRDMO) services company
.
Through an open and integrated biopharmaceutical capability and technology empowerment platform, the company provides a full range of end-to-end services to help partners discover, develop and produce biologics, realize the whole process from concept to commercial production, accelerate the global biopharmaceutical research and development process, reduce R&D costs, and benefit patients
.

WuXi Biologics has more than 10,000 employees
in China, the United States, Ireland, Germany and Singapore.
With the professional services team of these employees, as well as superior technology and insight, the company provides customers with efficient and cost-effective biopharmaceutical solutions
.
As of the end of June 2022, WuXi Biologics has helped customers develop and manufacture 534 integrated projects, including 14 commercial manufacturing projects
.

WuXi Biologics regards environmental, social and governance (ESG) as an important part of business development and entrepreneurial spirit, and is committed to becoming an ESG leader in the global biologics CRDMO field, such as applying greener next-generation biopharmaceutical technologies and energy
.
The company has established an ESG Committee led by the CEO to fully implement ESG strategies and demonstrate sustainability commitments
.

For more information, please visit: www.
wuxibiologics.
com

For more information, please contact

Media relations

PR@wuxibiologics.
com

Business inquiries

info@wuxibiologics.
com